目的 探讨多西他赛联合洛铂在三阴性乳腺癌(TNBC)新辅助化疗中的疗效和不良反应.方法 30例TN-BC患者应用多西他赛联合洛铂行新辅助化疗,具体方案为:多西他赛75mg/m2静滴,d1；洛铂30mg/m2静滴,d1；21天为1周期.按照WHO实体瘤客观疗效评价标准及术后病理组织学检测评价疗效,按照WHO急性及亚急性毒性标准评价毒副反应.结果 8、17和5例患者分别完成2、4和6个周期的新辅助化疗,获CR 9例、PR 15例、SD 4例、PD 2例,RR为80.0％；术后病理组织学检测获病理学完全缓解6例.主要不良反应为骨髓抑制:1 ～2级白细胞减少17例,3～4级5例；1～2级血小板减少7例,3～4级2例；1～2级血红蛋白减少6例.非血液学毒性轻微.结论 多西他赛联合洛铂方案的疗效较好,毒副反应可耐受,是TNBC新辅助化疗方案的一个新选择.%Objective To evaluate the efficacy and adverse reaction of neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in triple negative breast cancer (TNBC).Methods Thirty TNBC patients accepted neoadjuvant chemotherapy with docetaxel and lobaplatin(docetaxel 75mg/m2 iv,d1; lobaplatin 30mg/m2 iv,d1; 21 days was a cycle).The objective response and side effects were evaluated by WHO standard or histopathological reaction after surgery.Results Eight patients finished chemotherapy for 2 cycles,17 patients for 4 cycles and 5 patients for 6 cycles.All patients were evaluable,9 cases got CR,15 cases got PR,4 cases had SD,2 cases were PD.The clinical benefit rate was 80.0％.Six cases achieved pCR according to the histopathological detection after surgery.The main adverse reaction was myelosuppression,with grade 1-2 leukopenia in 17 cases,grade 3-4 leukopenia in 5 cases,grade 1-2 thrombocytopenia in 7 cases,grade 3-4 thrombocytopenia in 2 cases and grade 1-2 anemia in 6 cases.Non-hemotologic toxicities were modest and recoverable.Conclusion Neoadjuvant chemotherapy with docetaxel plus lobaplatin regimen in TNBC is effective and well tolerated,which gives us a new choice.
展开▼
